SunnyPharma provides independent health education for UK patients. Mounjaro (tirzepatide) begins affecting appetite within hours of the first injection — but the question most patients actually want answered is when they will see meaningful weight loss, and how much to expect at each dose stage. This guide answers both from clinical trial data, not marketing copy.
- Appetite suppression: begins within days of the first injection
- Visible weight loss: typically appears between weeks 4 and 8
- First month average: 1–4 kg at the 2.5 mg starting dose
- 72-week average: 15–20.9% of body weight lost depending on maintenance dose (SURMOUNT-1)
- NICE 5% rule: if less than 5% body weight lost after 6 months on highest tolerated dose, your prescriber must reassess
- Treatment duration: typically 6 to 18 months; some continue longer for maintenance
How Mounjaro Works in the Body — the Mechanism Behind the Timeline
Mounjaro contains tirzepatide, a dual GIP and GLP-1 receptor agonist. It works by mimicking two gut hormones that regulate appetite and blood sugar. The mechanism drives the timeline: the drug begins slowing gastric emptying — the rate at which food leaves the stomach — within hours of the first injection. That is why appetite changes often appear before any weight change on the scale.
GLP-1 activation reduces hunger signals and slows digestion. GIP activation strengthens the appetite-suppressing effect and supports insulin release. Together, they make smaller portions feel satisfying and reduce the frequency and intensity of food cravings. None of this is felt as a dramatic switch — the effect is gradual, which is by design. Mounjaro is a long-term treatment, not a fast-acting medication.
The starter dose is not about weight loss. The 2.5 mg starting dose used for the first four weeks is designed to let your body adjust to tirzepatide safely. Most patients see modest weight change at this stage. The dose then increases every four weeks, and weight loss typically accelerates with each step up.
Mounjaro Weight Loss by Week — What to Expect
The timeline below reflects the pattern seen in clinical trials and widely reported by patients. Individual results vary based on starting weight, diet, activity level, and how the dose is escalated.
Weeks 1–4 (2.5 mg starting dose)
Most patients notice reduced appetite within the first few days — food feels less appealing and smaller portions feel sufficient. Weight loss at this stage is modest: typically 1–2 kg for most patients, and sometimes less. Nausea is the most common side effect, usually peaking one to two days after injection and fading by day three to four. Smaller, lower-fat meals help during this phase. Do not interpret slow weight change in week one as the medication not working — the dose is intentionally low.
Weeks 5–8 (5 mg dose)
Appetite suppression becomes more pronounced at 5 mg. Most patients notice a clearer reduction in cravings and find it easier to eat smaller portions without feeling deprived. Weight loss typically accelerates: 0.5–1 kg per week is a common range. Some patients experience a brief return of nausea after the dose increase, which usually settles within a week. By the end of week 8, cumulative weight loss of 3–6 kg is typical, though the range is wide.
Weeks 9–16 (7.5 mg dose)
This is often when patients report the most noticeable shift in their relationship with food. Hunger becomes more predictable and manageable. Weight loss continues to build. Some patients reach their maintenance dose at 7.5 mg and stay here; others continue escalating. Clinical trial data shows this mid-escalation phase is where the dose-response relationship becomes clearly visible — higher doses produce meaningfully greater weight loss over time.
Months 4–18 (10 mg, 12.5 mg, 15 mg maintenance doses)
The greatest weight loss occurs with longer-term treatment at maintenance doses. SURMOUNT-1 trial participants who stayed on treatment for 72 weeks at higher doses achieved average weight reductions of 15–20.9% of starting body weight. Weight loss at this stage is gradual and steady — typically 0.2–0.5 kg per week — rather than dramatic. Plateaus are normal and do not indicate the medication has stopped working.
Mounjaro Weight Loss by Dose — SURMOUNT-1 Clinical Trial Data
The SURMOUNT-1 trial (Jastreboff et al., New England Journal of Medicine, 2022) is the primary clinical evidence for tirzepatide’s weight loss effects. It enrolled 2,539 adults with obesity or overweight and a weight-related comorbidity, randomized to tirzepatide or placebo alongside lifestyle intervention for 72 weeks. The figures below are average results from that trial.
| Maintenance dose | Average weight loss at 72 weeks | Patients losing ≥5% body weight | Patients losing ≥20% body weight |
|---|---|---|---|
| 5 mg | 15.0% | 89% | 30% |
| 10 mg | 19.5% | 94% | 50% |
| 15 mg | 20.9% | 96% | 57% |
| Placebo | 3.1% | 28% | 3% |
Source: Jastreboff et al. NEJM 2022. Participants received tirzepatide alongside diet and physical activity counseling. Results are averages; individual outcomes vary. Not all patients will reach or tolerate the 15 mg dose.
What these numbers mean in practice. A 20% reduction in body weight for someone starting at 100 kg means losing approximately 20 kg over 72 weeks — about 18 months. That is roughly 0.27 kg per week on average. Some weeks more, some weeks less, with the rate slowing as the body adapts. The trajectory is gradual by design.
How Long Does Mounjaro Take to Suppress Appetite?
Appetite suppression is typically the first effect patients notice — and it often appears before any meaningful change on the scale. This happens because tirzepatide begins slowing gastric emptying within hours of the first injection. Food stays in the stomach longer, which extends the feeling of fullness and delays the return of hunger after meals.
Most patients report noticeable appetite changes within the first three to seven days. Common early experiences include:
- Feeling full faster during meals and finding smaller portions sufficient
- Reduced interest in food between meals — snacking urges decrease
- Less intense food cravings, particularly for high-calorie foods
- Food that previously seemed appealing becoming less so
The appetite effect strengthens as the dose increases. At 2.5 mg it is noticeable but moderate; at maintenance doses of 10 mg or 15 mg it is considerably more pronounced. This is why weight loss accelerates through the escalation phase rather than peaking in week one.
How Long Do You Stay on Mounjaro in the UK?
Most patients in the UK use Mounjaro for between 6 and 18 months, though treatment length is always determined by the prescriber based on individual progress. There is no fixed duration — it is reviewed regularly.
Under NICE Technology Appraisal TA1026, the following continuation criterion applies:
The NICE 5% rule: If you have not lost at least 5% of your starting body weight after 6 months on your highest tolerated dose of Mounjaro, your prescriber is required by NICE guidance to reassess whether to continue treatment. This threshold applies to NHS prescribing. Private prescribers typically follow the same clinical standard.
If you are approaching this point without meeting the threshold, discuss it with your prescriber before the review — there may be dose, diet, or lifestyle adjustments that can change your trajectory.
For patients who reach their target weight, prescribers may discuss stepping down to a lower maintenance dose, stopping treatment while maintaining lifestyle habits, or continuing on the lowest effective dose. Weight regain after stopping is possible but is not inevitable for patients who have established sustainable eating and activity habits during treatment.
What If Mounjaro Stops Working?
Weight loss plateaus are a normal part of any treatment — they do not mean Mounjaro has stopped working. As body weight decreases, metabolic rate adapts. The body becomes more efficient, and the same calorie deficit produces slower weight loss over time. Clinical trial data reflects this: weight loss rate slows in the later months even as the total percentage continues to climb.
Genuine non-response — defined as less than 5% weight loss after 6 months at the highest tolerated dose — should prompt a prescriber review. Possible responses include adjusting the dose, reviewing diet and activity patterns, or considering an alternative medication. Never stop Mounjaro without discussing it with your prescriber first, as stopping can affect the patterns your body has adapted to during treatment.
Related UK GLP-1 Guides
Frequently Asked Questions
Mounjaro begins affecting appetite within hours of the first injection by slowing gastric emptying. Most patients notice reduced hunger within one to two weeks. Visible weight loss typically appears between weeks 4 and 8 as the dose escalates. Significant results — 15% or more of body weight — generally require 6 to 12 months of consistent treatment at maintenance doses.
In the first month, most patients lose between 1 and 4 kg. The first four weeks use the 2.5 mg starting dose, which is designed for tolerance rather than maximum weight loss. Greater weight loss accelerates from month 2 onward as the dose increases beyond 2.5 mg.
In the first week, Mounjaro begins slowing gastric emptying — food stays in the stomach longer, which reduces hunger and makes smaller portions feel satisfying. Many patients notice reduced appetite within the first few days. Weight on the scale may not change significantly yet; this is expected and does not mean the medication is not working.
According to SURMOUNT-1 trial data (Jastreboff et al., NEJM 2022), patients taking tirzepatide for 72 weeks lost an average of 15% of body weight on 5 mg, 19.5% on 10 mg, and 20.9% on 15 mg. These are averages from a controlled trial with lifestyle support; individual results vary based on diet, activity, and starting weight.
Appetite suppression typically begins within the first few days of starting Mounjaro. The initial effect on gastric emptying occurs after the first injection. As the dose increases over weeks and months, appetite suppression becomes stronger and more consistent.
Most patients in the UK stay on Mounjaro for 6 to 18 months depending on their progress and prescriber’s advice. Under NICE guidance (TA1026), if a patient has lost less than 5% of their starting weight after 6 months on their highest tolerated dose, the prescriber should reassess whether to continue treatment.
At 3 months you are typically still in the dose escalation phase — meaningful results often accelerate once maintenance doses of 10 mg or 15 mg are reached. The NICE 5% threshold applies at 6 months, not 3. Discuss any concerns with your prescriber before considering stopping.
Both Mounjaro and Wegovy suppress appetite within the first week and produce visible weight loss from weeks 4 to 8. Over 72 weeks, tirzepatide produces greater average weight loss (15–20.9% depending on dose) than semaglutide (14.9% at 2.4 mg). Both follow the same general pattern of gradual dose escalation over months.
Key factors include starting BMI, diet quality during treatment, physical activity level, how quickly the dose is escalated, and individual metabolic response. Consistent weekly injection timing also helps maintain steady drug levels and reduces side effects during dose changes.
Weight loss plateaus are normal and do not mean the medication has stopped working. The body adapts as weight decreases and metabolic rate adjusts. Clinical trial data shows weight loss becomes steadier and more gradual at higher doses over time, rather than stopping. A genuine plateau may signal a need to review dose, diet, or activity with your prescriber.
How we reviewed this article:
SunnyPharma follows strict sourcing guidelines and relies on peer-reviewed clinical trial data, government agencies (NICE, MHRA, NHS England), and manufacturer prescribing information. Dr. Swiggum’s review covers the clinical content. All weight loss figures are sourced from SURMOUNT-1 trial data (Jastreboff et al., NEJM 2022) and the Mounjaro Summary of Product Characteristics. SunnyPharma does not prescribe or sell medications.
Sources & References
- Jastreboff AM et al. — SURMOUNT-1: Tirzepatide once weekly for the treatment of obesity. NEJM 2022;387:205–216: nejm.org
- NICE Technology Appraisal TA1026 — Tirzepatide for managing overweight and obesity (December 2023): nice.org.uk
- Eli Lilly — Mounjaro (tirzepatide) UK Summary of Product Characteristics (SmPC): medicines.org.uk
- Farzam K, Patel P — Tirzepatide. StatPearls Publishing 2025: ncbi.nlm.nih.gov
- NHS England — Tier 3 weight management services commissioning guidance: england.nhs.uk
- MHRA — Mounjaro product information and licensing: gov.uk/mhra
- General Pharmaceutical Council — Online pharmacy register: pharmacyregulation.org
- Wilding JPH et al. — STEP 1: Once-weekly semaglutide in adults with overweight or obesity. NEJM 2021;384:989–1002: nejm.org
- NHS — Weight loss surgery and medicines: nhs.uk